Sorry, you need to enable JavaScript to visit this website.

INLYTA® (axitinib) Clinical Studies

14 CLINICAL STUDIES

14.1 First-Line Advanced RCC

INLYTA in Combination with Avelumab

The efficacy and safety of INLYTA in combination with avelumab was demonstrated in the JAVELIN Renal 101 trial (NCT02684006), a randomized, multicenter, open-label, study of INLYTA in combination with avelumab in 886 patients with untreated advanced RCC regardless of tumor PD-L1 expression [intent-to-treat (ITT) population]. Patients with autoimmune disease or conditions requiring systemic immunosuppression were excluded.

Randomization was stratified according to Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) (0 vs. 1) and region (United States vs. Canada/Western Europe vs. the rest of the world). Patients were randomized (1:1) to one of the following treatment arms:

  • INLYTA 5 mg twice daily orally was given in combination with avelumab 10 mg/kg intravenous infusion every 2 weeks (N=442). Patients who tolerated INLYTA 5 mg twice daily without Grade 2 or greater INLYTA-related adverse events for 2 consecutive weeks could increase to 7 mg and then subsequently to 10 mg twice daily. INLYTA could be interrupted or reduced to 3 mg twice daily and subsequently to 2 mg twice daily to manage toxicity.
  • Sunitinib 50 mg once daily orally for 4 weeks followed by 2 weeks off (N=444) until radiographic or clinical progression or unacceptable toxicity.

Treatment with INLYTA and avelumab continued until RECIST v1.1-defined progression of disease by Blinded Independent Central Review (BICR) assessment or unacceptable toxicity. Administration of INLYTA and avelumab was permitted beyond RECIST-defined disease progression if the patient was clinically stable and considered to be deriving clinical benefit by the investigator. Assessment of tumor status was performed at baseline, after randomization at 6 weeks, then every 6 weeks thereafter up to 18 months after randomization, and every 12 weeks thereafter until documented confirmed disease progression by BICR.

Baseline characteristics were a median age of 61 years (range: 27 to 88), 38% of patients were 65 years or older, 75% were male, 75% were White, and the ECOG PS was 0 (63%) or 1 (37%), respectively. Patient distribution by International Metastatic Renal Cell Carcinoma Database (IMDC) risk groups was 21% favorable, 62% intermediate, and 16% poor.

The major efficacy outcome measures were progression-free survival (PFS), as assessed by an BICR using RECIST v1.1 and overall survival (OS) in patients with PD-L1-positive tumors using a clinical trial assay (PD-L1 expression level ≥1%). Since PFS was statistically significant in patients with PD-L1-positive tumors [HR 0.61 (95% CI: 0.48, 0.79)], it was then tested in the ITT population and a statistically significant improvement in PFS in the ITT population was also demonstrated.

With a median overall survival follow-up of 19 months, overall survival data were immature with 27% deaths in the ITT population.

Efficacy results are presented in Table 7 and Figure 2.

Table 7: Efficacy Results from JAVELIN Renal 101 Trial-ITT
Efficacy Endpoints (Based on BICR Assessment) INLYTA plus avelumab
(N=422)
Sunitinib
(N=444)
BICR: Blinded Independent Central Review; CI: Confidence interval; NE: Not estimable.
*
p-value based on stratified log-rank.
Progression-Free Survival (PFS)
  Events (%) 180 (41) 216 (49)
  Median in Months (95% CI) 13.8 (11.1, NE) 8.4 (6.9, 11.1)
  Hazard ratio (95% CI) 0.69 (0.56, 0.84)
  2-sided p-value* 0.0002
Confirmed Objective Response Rate (ORR)
  Objective Response Rate n (%) 227 (51.4) 114 (25.7)
  (95% CI) (46.6, 56.1) (21.7, 30.0)
  Complete Response (CR) n (%) 15 (3.4) 8 (1.8)
  Partial Response (PR) n (%) 212 (48) 106 (24)

Figure 2. K-M Estimates for PFS Based on BICR Assessment - ITT

Figure 2

INLYTA in Combination with Pembrolizumab

The efficacy of INLYTA in combination with pembrolizumab was investigated in KEYNOTE-426 (NCT02853331), a randomized, multicenter, open-label trial conducted in 861 patients who had not received systemic therapy for advanced RCC. Patients were enrolled regardless of PD-L1 tumor expression status. Patients with active autoimmune disease requiring systemic immunosuppression within the last 2 years were ineligible. Randomization was stratified by International Metastatic RCC Database Consortium (IMDC) risk categories (favorable versus intermediate versus poor) and geographic region (North America versus Western Europe versus "Rest of the World").

Patients were randomized (1:1) to one of the following treatment arms:

  • INLYTA 5 mg orally, twice daily in combination with pembrolizumab 200 mg intravenously every 3 weeks up to 24 months. Patients who tolerated INLYTA 5 mg twice daily for 2 consecutive cycles (6 weeks) could increase to 7 mg and then subsequently to 10 mg twice daily. INLYTA could be interrupted or reduced to 3 mg twice daily and subsequently to 2 mg twice daily to manage toxicity.
  • Sunitinib 50 mg orally, once daily for 4 weeks and then off treatment for 2 weeks.

Treatment with INLYTA and pembrolizumab continued until RECIST v1.1-defined progression of disease or unacceptable toxicity. Administration of INLYTA and pembrolizumab was permitted beyond RECIST-defined disease progression if the patient was clinically stable and considered to be deriving clinical benefit by the investigator. Assessment of tumor status was performed at baseline, after randomization at Week 12, then every 6 weeks thereafter until Week 54, and then every 12 weeks thereafter.

The study population characteristics were: median age of 62 years (range: 26 to 90); 38% age 65 or older; 73% male; 79% White and 16% Asian; 19% and 80% of patients had a baseline KPS of 70 to 80 and 90 to 100, respectively; and patient distribution by IMDC risk categories was 31% favorable, 56% intermediate and 13% poor.

The main efficacy outcome measures were OS and PFS as assessed by BICR according to RECIST v1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. Additional efficacy outcome measures included ORR, as assessed by BICR. A statistically significant improvement in OS was demonstrated at the pre-specified interim analysis in patients randomized to INLYTA in combination with pembrolizumab compared with sunitinib. The trial also demonstrated statistically significant improvements in PFS and ORR. Table 8 and Figure 3 summarize the efficacy results for KEYNOTE-426. The median follow-up time was 12.8 months (range 0.1 to 22.0 months). Consistent results were observed across pre-specified subgroups, IMDC risk categories and PD-L1 tumor expression status.

Table 8: Efficacy Results in KEYNOTE-426
Endpoint INLYTA and Pembrolizumab
N=432
Sunitinib
N=429
CI: confidence interval; NR: not reached; ORR: objective response rate; OS: overall survival; PFS: progression-free survival.
*
Based on the stratified Cox proportional hazard model
Based on stratified log-rank test
p-Value (one-sided) is compared with the allocated alpha of 0.0001 for this interim analysis (with 39% of the planned number of events for final analysis).
§
p-Value (one-sided) is compared with the allocated alpha of 0.0013 for this interim analysis (with 81% of the planned number of events for final analysis).
Based on Miettinen and Nurminen method stratified by IMDC risk group and geographic region
OS
  Number of patients with event (%) 59 (14%) 97 (23%)
  Median in months (95% CI) NR (NR, NR) NR (NR, NR)
  Hazard ratio* (95% CI) 0.53 (0.38, 0.74)
  p-Value <0.0001
  12-month OS rate 90% (86, 92) 78% (74, 82)
PFS
  Number of patients with event (%) 183 (42%) 213 (50%)
  Median in months (95% CI) 15.1 (12.6, 17.7) 11.0 (8.7, 12.5)
  Hazard ratio* (95% CI) 0.69 (0.56, 0.84)
  p-Value 0.0001§
ORR
  Overall confirmed response rate (95% CI) 59% (54, 64) 36% (31, 40)
  Complete response rate 6% 2%
  Partial response rate 53% 34%
  p-Value <0.0001

Figure 3. Kaplan-Meier Curve for Overall Survival in KEYNOTE-426

Figure 3

14.2 Second-Line Advanced RCC

The safety and efficacy of INLYTA were evaluated in a randomized, open-label, multicenter Phase 3 study. Patients (N=723) with advanced RCC whose disease had progressed on or after treatment with 1 prior systemic therapy, including sunitinib-, bevacizumab-, temsirolimus-, or cytokine-containing regimens were randomized (1:1) to receive INLYTA (N=361) or sorafenib (N=362). Progression-free survival (PFS) was assessed by a blinded independent central review committee. Other endpoints included objective response rate (ORR) and overall survival (OS).

Of the patients enrolled in this study, 389 patients (54%) had received 1 prior sunitinib-based therapy, 251 patients (35%) had received 1 prior cytokine-based therapy (interleukin-2 or interferon-alfa), 59 patients (8%) had received 1 prior bevacizumab-based therapy, and 24 patients (3%) had received 1 prior temsirolimus-based therapy. The baseline demographic and disease characteristics were similar between the INLYTA and sorafenib groups with regard to age (median 61 years), gender (72% male), race (75% white, 21% Asian), Eastern Cooperative Oncology Group (ECOG) performance status (55% 0, 45% 1), and histology (99% clear cell).

There was a statistically significant advantage for INLYTA over sorafenib for the endpoint of PFS (see Table 9 and Figure 4). There was no statistically significant difference between the arms in OS.

Table 9: Efficacy Results
Endpoint/Study Population INLYTA Sorafenib HR (95% CI) P-value
CI: Confidence interval; HR: Hazard ratio (INLYTA/sorafenib); ITT: Intent-to-treat; ORR: Objective response rate; NS: Not significant; OS: Overall survival; PFS: Progression-free survival
*
Time from randomization to progression or death due to any cause, whichever occurs first.
Assessed by independent radiology review according to RECIST.
One-sided p-value from a log-rank test of treatment stratified by ECOG performance status and prior therapy (comparison is considered statistically significant if the one-sided p-value is <0.023).
§
Risk ratio is used for ORR. A risk ratio >1 indicated a higher likelihood of responding in the axitinib arm; a risk ratio <1 indicated a higher likelihood of responding in the sorafenib arm.
P-value not included since it was not adjusted for multiple testing.
Overall ITT N= 361 N = 362
Median PFS*, in months (95% CI) 6.7 (6.3, 8.6) 4.7 (4.6, 5.6) 0.67 (0.54, 0.81) <0.0001
Median OS in months
(95% CI)
20.1 (16.7, 23.4) 19.2 (17.5, 22.3) 0.97 (0.80, 1.17) NS
ORR % (95% CI) 19.4 (15.4, 23.9) 9.4 (6.6, 12.9) 2.06§ (1.41, 3.00) -
PFS by prior treatment
Sunitinib-refractory subgroup N=194 N=195
  Median, months (95% CI) 4.8 (4.5, 6.4) 3.4 (2.8, 4.7) 0.74 (0.57, 0.96) -
Cytokine-refractory subgroup N=126 N=125
  Median, months (95% CI) 12.1 (10.1, 13.9) 6.5 (6.3, 8.3) 0.46 (0.32, 0.68) -

Figure 4. Kaplan-Meier Curve for Progression-Free Survival by Independent Assessment (Intent-to-Treat Population)

Figure 4

What's New

No Current Announcements.

Contact Pfizer Medical

Search

Please enter your search term(s) for INLYTA®
×

Sollten Sie Probleme mit der Anmeldung über Ihr DocCheck Konto haben, deaktivieren Sie „Cross-Sitetracking verhindern“ unter Einstellungen / Safari / Datenschutz & Sicherheit.

×

Ihre derzeitige Browsereinstellung erlaubt keine Anmeldung über Ihr DocCheck Konto. Bitte wählen Sie den „Desktop-Version“ Modus unter dem Dreipunkt-Menu Ihres Browsers.

×

Safari-Nutzer: Sollten Sie Probleme mit der Anmeldung über Ihr DocCheck Konto haben, deaktivieren Sie „Cross-Sitetracking verhindern“ unter Einstellungen / Safari / Datenschutz & Sicherheit.